Drug-Eluting Stents - Global Strategic Business Report 2017 - Leading Players are Abbott Laboratories, Boston Scientific, and Medtronic

Dublin, June 21, 2017 -- Research and Markets has announced the addition of the "Drug-Eluting Stents - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 35 companies including many key and niche players such as

• Abbott Laboratories (US)
• AlviMedica (Turkey)
• Arterius Limited (UK)
• B. Braun Melsungen AG (Germany)
• Biosensors International Group, Ltd. (Singapore)
• Shandong JW Medical Systems LTD. (China)
• Biotronik SE & Co. KG (Germany)
• Boston Scientific Corporation (US)
• Cook Medical Inc. (US)
• Elixir Medical Corp. (US)
• KYOTO MEDICAL PLANNING Co., Ltd. (Japan)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• Medtronic plc (Republic of Ireland)
• Micell Technologies, Inc. (US)
• Opto Circuits (India) Ltd (India)
• Eurocor GmbH (Germany)
• OrbusNeich Medical Company Limited (Hong Kong)
• QualiMed (Germany)
• Shanghai MicroPort Medical (Group) Co., Ltd. (China)
• Sino Medical Sciences Technology Inc. (China)
• STENTYS SA (France)
• Terumo Corporation (Japan)

Key Topics Covered:

1. Industry Overview

• Coronary Stents Market - A Prelude
• Key Market Drivers & Restraints
• Competitive Scenario
• J&J Exit from DES Market Improves Prospects for Competitors
• Evolution of the Drug-Eluting Stent
• Evolution of Drug-Eluting Stents (DES) Over the Years
• Comparative Analysis of Drug-Eluting Stents in Terms of
• Physical Parameters
• Bioabsorbable Stents
• New Stents with Biodegradable Polymers
• Completely Bioresorbable Scaffolds: Potential Game-Changer
• Noteworthy Clinical Studies and Innovations
• Study Proves Efficacy of Very Thin Strut DES On Par with
• Durable Polymer Stents
• Drug-Eluting Stents and Drug-Coated Balloons for Non-Coronary
• Indications
• DES for Large Sized Arteries
• Addressing the Unmet Challenges in Patients with Diabetes
• Biosensors Commercializes BMX-J DES System
• SLENDER DES Set to Downsize the Future of Interventional
• Cardiology
• Other Novel DES Launches
• Researchers at University of Strathclyde Evaluate VAN 10-4
• Small Molecule
• DES Safe for Vein Grafts Procedures

2. Macro Growth Drivers

• Aging - A Key Market Driver
• Global Aging Population Demographic Statistics: Key Opportunity Indicator
• High Diabetes Incidence Worldwide Drives Demand for Cardiac Surgery and Stents

3. Coronary Stenting - An Insight

• Cardiovascular Diseases - A Brief Description
• Coronary Heart Disease
• Treatment Options for Coronary Artery Disease
• Percutaneous Transluminal Coronary Angioplasty (PTCA)
• Coronary Artery Bypass Graft (CABG)
• Coronary Stenting
• How is Coronary Stenting Performed - Procedure
• Risks and Problems Associated with Placing a Stent
• Restenosis - A Major Challenge
• Cost and Price Economics of DES
• Cost Evaluation of DES
• Impact of DES on Indirect Costs

4. Product Launches & Approvals

• MicroPort Medical Receives Marketing Approval in Argentina for Firehawk® DES
• MicroPort Medical's Firehawk® DES Receives Marketing Approval in Brazil
• Biotronik Launches Biostem Clinical Trial for Orsiro Hybrid DES
• Boston Scientific's Eluvia DES System Receives CE Mark
• STENTYS Enters into Commercialization Agreements in Europe for below-the-knee arterial DES
• Medtronic Launches Expanded Sizes of Onyx DES and Expands Indications
• Svelte Medical Launches SLENDER Coronary Stent System in Europe
• Boston Scientific Receives FDA Approval for SYNERGY DES System
• Medtronic Launches Resolute Onyx DES in India
• BIOTRONIK Announces Positive Clinical Trial Data of Orsiro Hybrid DES
• Medtronic Begins Clinical Studies for Resolute Onyx DES in the US
• Alvimedica's Cre8 DES Receives CE Mark
• Medtronic Announces CE Mark Approval and International Launch of Resolute Onyx DES
• Cook Medical Launches Zilver PTX DES in Canada
• Boston Scientific Launches Promus PREMIER DES in Japan
• Terumo Corporation Receives CE Mark Approval for Ultimaster DES

5. Recent Industry Activity

• Cordis Enters into Coronary Stent Sales Agreement with Biosensors International
• MicroPort Scientific Acquires DES Assets and Intellectual Property from Cordis

6. Focus On Select Global Players

7. Global Market Perspective

For more information about this report visit https://www.researchandmarkets.com/research/t5wq5d/drugeluting

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Drug Delivery, Stents